Hopital Prive Des Cotes D'armor — Clinical Trial Site

58 Registered trials

26 Currently recruiting

Organisation

Hopital Prive Des Cotes D'armor

Location

Plerin, France

Identifier

ORG-100044260

Address

10 Rue Francois Jacob, 22190, France

Departments

-
1201: Service oncologie
2307: Service Oncologie
CARIO – HPCA, Oncologie Médicale
CARIO Medical Oncology
CBU
Chirurgie urologique
Département d'oncologie
Département d'Oncologie Médicale
Department of Medical Oncology
Department of Oncology
Medical Oncology
Medical Oncology Department
N/A
NA
Oncologie
Oncologie médicale
Oncology
Oncology-Radiotherapy
Service d'hospitalisation
Service d'oncologie médicale
Service d’Oncologie Médicale
Service Oncologie

Clinical trials at this site (58)

Search interface

TRAK-ER_A randomised trial of early detection of molecular relapse with circulating tumour DNA tracking and treatment with palbociclib plus … Recruiting

2024-517414-15-00 ER positive HER2 negative breast cancer 4 2023-01-25
Evaluation of an initial treatment with bevacizumab in combination with chemotherapy and then in combination with niraparib in maintenance i… Recruiting

2023-504166-37-00 Advanced ovarian, tubal or peritoneal cancer. 4 2022-02-01
Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting

2024-512982-15-00 BRCA Mutated Ovarian Cancer Patients, Epithelian ovaria 5 2021-06-28
A Study of Zolbetuximab Together with Pembrolizumab and Chemotherapy in Adults with Gastric Cancer Ended

2024-519773-19-00 Gastroesophageal Junction Adenocarcinoma 5 2025-07-31
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended

2022-502369-10-00 Triple negative metastatic breast cancer 5 2023-10-02
Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With HR+/HER2− Metastatic Breast Cancer Who Have Received … Ended

2022-502593-17-00 Locally advanced or metastatic hormone receptor (HR)-po 5 2023-09-19
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A clinical trial of relacorilant (study drug) with nab-paclitaxel in patients with ovarian, fallopian tube or peritoneal cancer Ended

2024-514080-25-00 Advanced, Platinum-Resistant, High-Grade Epithelial Ova 5 2023-04-21
PRODIGE 81-FFCD 2101-TRIPLET: Study evaluating the benefit of adding Ipilimumab to the combination of Atezolizumab and Bevacizumab in patien… Ended

2022-501217-31-00 Hepatocellular carcinoma 10 2023-03-09
A safety and efficacy study of treatment combinations with and without chemotherapy in adult patients with advanced upper gastrointestinal t… Ended

2024-511917-40-00 Advanced Upper Gastrointestinal Tract Malignancies 4 2022-09-13
Randomized phase III trial in MMR deficient endometrial cancer patients comparing chemotherapy alone versus Dostarlimab in first line advanc… Ended

2023-510097-14-00 Patients with MMR deficient relapse or advanced / metas 5 2022-04-15
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
Multi-drug treatment for breast cancer patients with brain metastases Ended

2024-510703-11-00 HER2+ metastatic breast cancer with isolated brain prog 4 2021-12-13
Phase Ib/III Study of Capivasertib + CDK4/6 Inhibitors + Fulvestrant as Treatment for Advanced/Metastatic HR+/HER2-Breast Cancer (CAPItello-… Ended

2023-504997-39-00 Hormone Receptor-Positive and Human Epidermal Growth Fa 5 2021-06-14
An Umbrella Study of INCMGA00012 Alone and in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cance… Ended

2022-502600-79-00 Endometrial cancer 4 2021-03-16
Sacituzumab Govitecan in primary HER2-negative breast cancer (SASCIA) Ended

2023-510390-33-00 HER2-negative breast cancer patients with high relapse 5 2020-10-23
Phase III Study of Capivasertib + Fulvestrant vs Placebo + Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2… Ended

2023-505042-25-00 Locally advanced (inoperable) or metastatic HR+/HER2 br 5 2020-05-05
Association of Radiochemotherapy and Immunotherapy for the Treatment of Unresectable Oesophageal caNcer Ended

2024-512165-13-00 Localised unresectable adenocarcinoma or squamous cell 4 2019-05-13
A Study of Zolbetuximab (IMAB362) in Adults with Pancreatic Cancer Ended

2024-510985-17-00 First Line Treatment in Subjects with Claudin 18.2 (CLD 4 2019-03-14
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer 5 2018-11-27
Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Ended

2024-513964-24-00 Squamous cell carcinoma, previously untreated Stage III 5 2017-09-14
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer (monarchE) Ended

2023-509671-17-00 Breast Cancer 5 2017-07-12
Comparison FOLFIRINOX Panitumumab vs mFOLFOX6 Panitumumab in RAS/B-RAF Wild-type Metastatic Colorectal Cancer Patients (PANIRINOX) Ended

2024-510645-34-00 RAS and B-RAF wild-type metastatic colorectal cancer. R 4 2017-06-28